يحاول ذهب - حر
"Evolving regulatory requirements, heightened scrutiny from regulatory agencies, and geopolitical uncertainties pose challenges"
BioSpectrum India May 2025
|Bio Spectrum
Strides Pharma Science demerged its Contract Development and Manufacturing Organisation (CDMO) business into OneSource Specialty Pharma Ltd, following approval by the National Company Law Tribunal (NCLT) in 2024.
-

OneSource Specialty Pharma, was listed on January 22, 2025 on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). With a revenue generation of around Rs 1500 crore during FY 2024-25, the company is providing seamless end-to-end offerings across all verticals (biologics, drug-device combinations, sterile injectables and Softgel capsules). In an interaction with BioSpectrum India, Neeraj Sharma, CEO & Managing Director, OneSource Specialty Pharma, upbeat about the growth of the CDMO sector, reveals more about the company's major focus areas in the coming years. Edited excerpts:
What have been the major highlights for this fiscal, and what are your upcoming plans?
This fiscal has been marked by significant milestones, namely the successful merger of the three incoming businesses, fundraising with participation from marquee investors, successful listing on the NSE and the BSE and significant addition to our customer base. The listing of OneSource Pharma on the NSE and BSE this year, marks a significant milestone in our journey, one that began with a vision to build a one-stop shop for the CDMO sector. Listing will increase our visibility among partners and stakeholders, opening up more opportunities for strategic collaborations and business ventures. It will also support the recruitment of talent from around the globe. The group is known for its strong corporate governance. We now have over 60 customers across all modalities and now we collaborate with 20 customers in the GLP-1 space. We have initiated our first new biological entity (NBE) programme with the top three animal health companies. Additionally, we are supporting seven potential new chemical entity (NCE)-1 programmes.
هذه القصة من طبعة BioSpectrum India May 2025 من Bio Spectrum.
اشترك في Magzter GOLD للوصول إلى آلاف القصص المتميزة المنسقة، وأكثر من 9000 مجلة وصحيفة.
هل أنت مشترك بالفعل؟ تسجيل الدخول
المزيد من القصص من Bio Spectrum

Bio Spectrum
India's Pharma Reforms Target Global Credibility
The Indian government has introduced several measures to simplify drug approvals and support innovation.
9 mins
October 2025

Bio Spectrum
How Waste Management Strategies Can Transform Indian Pharma Manufacturing
Sustainability will be a key success factor as India's pharmaceutical industry enters its next stage of expansion.
7 mins
October 2025

Bio Spectrum
IASST synthesises new compound to combat aggressive breast cancer
A newly designed nitro-substituted organoselenium compound by Guwahati-based Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), can reduce the invasiveness of aggressive triplenegative breast cancer cells by modulating various Se Se signalling pathways.
1 min
October 2025
Bio Spectrum
DPIIT signs MoU with Pfizer to strengthen healthcare innovation ecosystem
In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.
1 min
October 2025

Bio Spectrum
WHO unveils updated guideline on HIV service delivery
WHO has released an updated guideline to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy (ART), and improve the overall health and well-being of people living with HIV.
1 min
October 2025
Bio Spectrum
Scientists in Kolkata explore therapeutic potential of accessory proteins
A hidden protein that protects our cells from mechanical stress could provide a new direction to therapeutic strategies for diseases where protein stability under force is compromised like heart muscle disease or genetic disorders called laminopathies.
1 min
October 2025

Bio Spectrum
US FDA advances rare disease drug development
The US Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.
1 min
October 2025
Bio Spectrum
WHO updates list of essential medicines to include key cancer, diabetes treatments
The World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLC), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.
1 min
October 2025
Bio Spectrum
Agilent's MMR IHC Panel pharmDx (Dako Omnis) receives European IVDR Certification
Agilent Technologies Inc. has announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer.
1 min
October 2025
Bio Spectrum
Aodh Lifesciences gets support from TDB to redefine pneumonia treatment
The Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to Aodh Lifesciences, a startup based in Hyderabad, for development of Indigenous Antibiotic Nebulisation Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).
1 min
October 2025
Listen
Translate
Change font size